Zobrazeno 1 - 10 of 1 581 pro vyhledávání: '"Blatt LM"'
1
Akademický článek
The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075.
Autor: Vendeville S; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium., Amblard F; Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, 100 Woodruff Circle, Atlanta, Georgia 30322, United States., Bassit L; Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, 100 Woodruff Circle, Atlanta, Georgia 30322, United States., Beigelman LN; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Blatt LM; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Chen X; WuXi AppTec, 288 Fute Zhong Road Waigaoqiao Free Trade Zone, Pudong New Area, Shanghai, 200131, China., Chou L; WuXi AppTec, 288 Fute Zhong Road Waigaoqiao Free Trade Zone, Pudong New Area, Shanghai, 200131, China., Kum DB; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium., Chanda S; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Deval J; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Geng X; WuXi AppTec, 288 Fute Zhong Road Waigaoqiao Free Trade Zone, Pudong New Area, Shanghai, 200131, China., Gupta K; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Jekle A; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Hu H; Pharmaron Beijing Co Ltd, 6 Taihe Road, BDA, Beijing 100176, China., Hu X; Pharmaron Beijing Co Ltd, 6 Taihe Road, BDA, Beijing 100176, China., Kang H; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Liu C; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Liu J; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., McGowan DC; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium., Misner DL; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Raboisson P; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium., Sanchez AA; Novalix, Gaston Geenslaan 1, 3001 Leuven, Belgium., Serebryany V; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Stoycheva AD; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Symons JA; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Tan H; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Vanrusselt H; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium., Williams C; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Welch M; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Zhang L; Pharmaron Beijing Co Ltd, 6 Taihe Road, BDA, Beijing 100176, China., Zhang Q; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Zhang Y; WuXi AppTec, 288 Fute Zhong Road Waigaoqiao Free Trade Zone, Pudong New Area, Shanghai, 200131, China., Schinazi RF; Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, 100 Woodruff Circle, Atlanta, Georgia 30322, United States., Smith DB; Aligos Therapeutics, Inc., 1 Corporate Dr., Second Floor, South San Francisco, California 94080, United States., Debing Y; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Nov 22. Date of Electronic Publication: 2024 Nov 22.
Zobrazit plný text záznamu
2
Akademický článek
Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH.
Autor: Vandyck K; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium., McGowan DC; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium., Luong XG; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States., Stevens SK; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States., Jekle A; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States., Gupta K; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States., Misner DL; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States., Chanda S; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States., Serebryany V; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States., Welch M; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States., Hu H; Pharmaron, 6 Taihe Road, BDA, Beijing, 100176, P. R. China., Lv Z; Pharmaron, 6 Taihe Road, BDA, Beijing, 100176, P. R. China., Williams C; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States., Maskos K; Proteros Biostructures GmbH, Bunsenstraße 7a, 82152 Planegg-Martinsried, Germany., Lammens A; Proteros Biostructures GmbH, Bunsenstraße 7a, 82152 Planegg-Martinsried, Germany., Stoycheva AD; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States., Lin TI; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium., Blatt LM; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States., Beigelman LN; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States., Symons JA; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States., Raboisson P; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States., Deval J; Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Sep 12; Vol. 67 (17), pp. 14840-14851. Date of Electronic Publication: 2024 Sep 02.
Zobrazit plný text záznamu
4
Akademický článek
An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients.
Autor: Debing Y; Aligos Belgium BV, Leuven, Belgium. Electronic address: ydebing@aligos.com., Vanrusselt H; Aligos Belgium BV, Leuven, Belgium., Degrauwe L; Laboratory of Host Pathogen Interactions, Department of Biosystems, KU Leuven, Leuven, Belgium., Silva de Oliveira DA; Laboratory of Host Pathogen Interactions, Department of Biosystems, KU Leuven, Leuven, Belgium., Kariuki CK; Laboratory of Host Pathogen Interactions, Department of Biosystems, KU Leuven, Leuven, Belgium., Ebwanga EJ; Laboratory of Host Pathogen Interactions, Department of Biosystems, KU Leuven, Leuven, Belgium., Bashir S; Laboratory of Host Pathogen Interactions, Department of Biosystems, KU Leuven, Leuven, Belgium., Merckx W; TRANSfarm, Science, Engineering & Technology Group, KU Leuven, Leuven, Belgium., Thatikonda SK; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Rajwanshi V; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Gohil V; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Hong J; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Kum DB; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Acosta Sanchez A; Novalix, Braine-l'Alleud, Belgium., Chanda S; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Blatt LM; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Jekle A; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Symons JA; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Smith DB; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Raboisson P; Aligos Belgium BV, Leuven, Belgium., Lin TI; Aligos Belgium BV, Leuven, Belgium., Beigelman L; Aligos Therapeutics, Inc., South San Francisco, CA, USA., Paeshuyse J; Laboratory of Host Pathogen Interactions, Department of Biosystems, KU Leuven, Leuven, Belgium. Electronic address: jan.paeshuyse@kuleuven.be.
Publikováno v: Antiviral research [Antiviral Res] 2024 Apr; Vol. 224, pp. 105835. Date of Electronic Publication: 2024 Feb 23.
Zobrazit plný text záznamu
5
Akademický článek
Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models.
Autor: Jekle A; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Thatikonda SK; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Jaisinghani R; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Ren S; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Kinkade A; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Stevens SK; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Stoycheva A; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Rajwanshi VK; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Williams C; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Deval J; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Mukherjee S; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Zhang Q; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Chanda S; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Smith DB; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Blatt LM; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Symons JA; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA., Gonzalvez F; Aligos Belgium BV, 3001 Leuven, Belgium., Beigelman L; Aligos Therapeutics, Inc., South San Francisco, CA 94080, USA.
Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2023 Nov 13; Vol. 24 (22). Date of Electronic Publication: 2023 Nov 13.
Zobrazit plný text záznamu
6
Akademický článek
Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles.
Autor: Vanrusselt H; Aligos Belgium BV , Leuven, Belgium., Kum DB; Aligos Belgium BV , Leuven, Belgium.; Aligos Therapeutics, Inc. , South San Francisco, California, USA., Taverniti V; Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMR S1110, Université de Strasbourg , Strasbourg, France., Liu C; Aligos Therapeutics, Inc. , South San Francisco, California, USA., Acosta Sanchez A; Novalix , Leuven, Belgium., Corthout N; VIB Bio-imaging Core , Leuven, Belgium., Munck S; VIB Bio-imaging Core , Leuven, Belgium., Baumert TF; Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMR S1110, Université de Strasbourg , Strasbourg, France.; Service d'Hépato-gastroenterologie, Pôle Hépato-digestif, IHU Strasbourg, Strasbourg University Hospitals , Strasbourg, France., Beigelman L; Aligos Therapeutics, Inc. , South San Francisco, California, USA., Blatt LM; Aligos Therapeutics, Inc. , South San Francisco, California, USA., Symons JA; Aligos Therapeutics, Inc. , South San Francisco, California, USA., Deval J; Aligos Therapeutics, Inc. , South San Francisco, California, USA., Raboisson P; Aligos Belgium BV , Leuven, Belgium., Verrier ER; Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMR S1110, Université de Strasbourg , Strasbourg, France., Jekle A; Aligos Therapeutics, Inc. , South San Francisco, California, USA., Vendeville S; Aligos Belgium BV , Leuven, Belgium., Debing Y; Aligos Belgium BV , Leuven, Belgium.
Publikováno v: Journal of virology [J Virol] 2023 Oct 31; Vol. 97 (10), pp. e0072223. Date of Electronic Publication: 2023 Sep 27.
Zobrazit plný text záznamu
7
Akademický článek
Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.
Autor: Kum DB; Aligos Belgium BV, Leuven, Belgium.; Aligos Therapeutics Inc., South San Francisco, California, USA., Vanrusselt H; Aligos Belgium BV, Leuven, Belgium., Acosta Sanchez A; Novalix, Leuven, Belgium., Taverniti V; Strasbourg University, Inserm, Institute for Research on Viral and Hepatic Diseases, UMR S1110, Strasbourg, France., Verrier ER; Strasbourg University, Inserm, Institute for Research on Viral and Hepatic Diseases, UMR S1110, Strasbourg, France., Baumert TF; Strasbourg University, Inserm, Institute for Research on Viral and Hepatic Diseases, UMR S1110, Strasbourg, France.; Hepato-digestive Division, IHU Strasbourg, Strasbourg University Hospitals, Strasbourg, France., Liu C; Aligos Therapeutics Inc., South San Francisco, California, USA., Deval J; Aligos Therapeutics Inc., South San Francisco, California, USA., Corthout N; VIB Bio-imaging Core, Leuven, Belgium., Munck S; VIB Bio-imaging Core, Leuven, Belgium., Beigelman L; Aligos Therapeutics Inc., South San Francisco, California, USA., Blatt LM; Aligos Therapeutics Inc., South San Francisco, California, USA., Symons JA; Aligos Therapeutics Inc., South San Francisco, California, USA., Raboisson P; Aligos Belgium BV, Leuven, Belgium., Jekle A; Aligos Therapeutics Inc., South San Francisco, California, USA., Vendeville S; Aligos Belgium BV, Leuven, Belgium., Debing Y; Aligos Belgium BV, Leuven, Belgium.
Publikováno v: Hepatology (Baltimore, Md.) [Hepatology] 2023 Oct 01; Vol. 78 (4), pp. 1252-1265. Date of Electronic Publication: 2023 Apr 28.
Zobrazit plný text záznamu
8
Akademický článek
The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir.
Autor: Jochmans D; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium., Liu C; Aligos Therapeutics, Inc., South San Francisco, California, USA., Donckers K; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium., Stoycheva A; Aligos Therapeutics, Inc., South San Francisco, California, USA., Boland S; CISTIM Leuven vzw, Leuven, Belgium., Stevens SK; Aligos Therapeutics, Inc., South San Francisco, California, USA., De Vita C; Aligos Therapeutics, Inc., South San Francisco, California, USA., Vanmechelen B; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Clinical & Epidemiological Virology, Leuven, Belgium., Maes P; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Clinical & Epidemiological Virology, Leuven, Belgium., Trüeb B; Institute of Virology and Immunology, University of Bern, Bern, Switzerland., Ebert N; Institute of Virology and Immunology, University of Bern, Bern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland., Thiel V; Institute of Virology and Immunology, University of Bern, Bern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland., De Jonghe S; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium., Vangeel L; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium., Bardiot D; CISTIM Leuven vzw, Leuven, Belgium., Jekle A; Aligos Therapeutics, Inc., South San Francisco, California, USA., Blatt LM; Aligos Therapeutics, Inc., South San Francisco, California, USA., Beigelman L; Aligos Therapeutics, Inc., South San Francisco, California, USA., Symons JA; Aligos Therapeutics, Inc., South San Francisco, California, USA., Raboisson P; Aligos Belgium BV, Leuven, Belgium., Chaltin P; CISTIM Leuven vzw, Leuven, Belgium.; Centre for Drug Design and Discovery (CD3), KU Leuven, Leuven, Belgium., Marchand A; CISTIM Leuven vzw, Leuven, Belgium., Neyts J; KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Laboratory of Virology & Chemotherapy, Leuven, Belgium.; Global Virus Network (GVN), Baltimore, Maryland, USA., Deval J; Aligos Therapeutics, Inc., South San Francisco, California, USA., Vandyck K; Aligos Belgium BV, Leuven, Belgium.
Publikováno v: MBio [mBio] 2023 Feb 28; Vol. 14 (1), pp. e0281522. Date of Electronic Publication: 2023 Jan 10.
Zobrazit plný text záznamu
9
Akademický článek
Mechanism of action of hepatitis B virus S antigen transport-inhibiting oligonucleotide polymer, STOPS, molecules.
Autor: Kao CC; Aligos Therapeutics, Inc., 1 Corporate Drive, South San Francisco, CA 94080, USA., Nie Y; Aligos Therapeutics, Inc., 1 Corporate Drive, South San Francisco, CA 94080, USA., Ren S; Aligos Therapeutics, Inc., 1 Corporate Drive, South San Francisco, CA 94080, USA., De Costa NTTS; Aligos Therapeutics, Inc., 1 Corporate Drive, South San Francisco, CA 94080, USA., Pandey RK; Aligos Therapeutics, Inc., 1 Corporate Drive, South San Francisco, CA 94080, USA., Hong J; Aligos Therapeutics, Inc., 1 Corporate Drive, South San Francisco, CA 94080, USA., Smith DB; Aligos Therapeutics, Inc., 1 Corporate Drive, South San Francisco, CA 94080, USA., Symons JA; Aligos Therapeutics, Inc., 1 Corporate Drive, South San Francisco, CA 94080, USA., Beigelman L; Aligos Therapeutics, Inc., 1 Corporate Drive, South San Francisco, CA 94080, USA., Blatt LM; Aligos Therapeutics, Inc., 1 Corporate Drive, South San Francisco, CA 94080, USA.
Publikováno v: Molecular therapy. Nucleic acids [Mol Ther Nucleic Acids] 2021 Dec 11; Vol. 27, pp. 335-348. Date of Electronic Publication: 2021 Dec 11 (Print Publication: 2022).
Zobrazit plný text záznamu
10
Akademický článek
ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model.
Autor: Vandyck K; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium. Electronic address: kvandyck@aligos.com., Abdelnabi R; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Gupta K; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Jochmans D; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Jekle A; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Deval J; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Misner D; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Bardiot D; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium., Foo CS; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Liu C; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Ren S; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Beigelman L; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Blatt LM; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Boland S; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium., Vangeel L; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Dejonghe S; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Chaltin P; Centre for Drug Design and Discovery (CD3), KU Leuven, Gaston Geenslaan 2, 3001 Leuven, Belgium; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium., Marchand A; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium., Serebryany V; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Stoycheva A; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Chanda S; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Symons JA; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Raboisson P; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium., Neyts J; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium. Electronic address: johan.neyts@kuleuven.be.
Publikováno v: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2021 May 28; Vol. 555, pp. 134-139. Date of Electronic Publication: 2021 Mar 26.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje